Geode Capital Management, LLC Cyclo Therapeutics, Inc. Transaction History
Geode Capital Management, LLC
- $1.07 Trillion
- Q1 2024
A detailed history of Geode Capital Management, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 159,749 shares of CYTH stock, worth $193,296. This represents 0.0% of its overall portfolio holdings.
Number of Shares
159,749
Previous 152,077
5.04%
Holding current value
$193,296
Previous $241,000
7.88%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CYTH
# of Institutions
22Shares Held
2.16MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA854KShares$1.03 Million0.47% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$581,6563.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA397KShares$479,9560.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$133,12757.89% of portfolio
-
State Street Corp Boston, MA39.5KShares$47,8310.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $10.2M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...